Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-04-05
2011-04-05
Wen, Sharon (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S130100, C424S133100, C424S135100, C424S144100, C530S387100, C530S387300, C530S388230, C435S810000, C435S975000
Reexamination Certificate
active
07919089
ABSTRACT:
The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
REFERENCES:
patent: 195 31 348 (1997-02-01), None
patent: WO 99/25818 (1999-05-01), None
patent: WO 00/03016 (2000-01-01), None
patent: WO 00/06605 (2000-02-01), None
patent: WO 01/71005 (2001-09-01), None
Flieger et al. Cancer Immuno. Immunother., 2000, 49:441-448.
Padlan et al. PNAS 1989, 86:5938-5942.
Bendig Methods: A Companion to Methods in Enzymology 1995; 8:83-93.
Klimka et al. British Journal of Caner 2000, 83:252-260.
Beiboer et al. J. Mol. Biol. 2000, 296:833-849.
MacCallum et al. J. Mol. Biol. 1996, 262:732-745.
Lamminmaki et al. JBC 2001, 276:36687-36694.
Barbas et al. PNAS 1995, 92:2529-2533.
Attwood Science 290: 471-473, 2000.
Skolnick et al. Trends in Biotech. 18: 34-39, 2000.
Rudikoff et al. PNAS 1982 79:1979.
Johnson et al., “Preferred CDRH3 lengths for antibodies with defined specificities,” International Immunology, Dec. 1998, vol. 10, No. 12, pp. 1801-1805.
Raum et al., “Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens,” Cancer Immunol. Immunother., May 2001, vol. 50, No. 3, pp. 141-150.
M. Balzar et al., “The biology of the 17-1A antigen (Ep-CAM),”J Mol Med, 1999, 77:699-712.
Sarita Chaubal et al. “Ep-CAM—A Marker for the Detection of Disseminated Tumor Cells in Patients Suffering from SCCHN,”Anticancer Research, 19: 2237-2242 (1999).
R. De Bree, et al., “Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targetting tumours in the upper aerodigestive and respiratory tract,”Nuclear Medicine Communications(1994) 15, 613-627.
Günther Gastl et al., “Ep-CAM overexpression in breast cancer as a predictor of survival,”The Lancet, vol. 356, Dec. 9, 2000.
Heinrich G. Göttlinger et al., “The Epithelial Cell Surface Antigen 17-1A, A Target for Antibody-Mediated Tumor Therapy: Its Biochemical Nature, Tissue Distribution and Recognition by Different Monoclonal Antibodies,”Int. J. Cancer, 38:47-53 (1986).
Wijnand Helfrich et al., “Construction and Characterization of a Bispecific Diabody for Retargeting T Cells to Human Carcinomas,”Int. J. Cancer: 76, 232-239 (1998).
George Johnson et al., “Preferred CDRH3 lengths for antibodies with defined specificities,”International Immunology, vol. 10, No. 12, pp. 1801-1805 (1998).
Bart-Jan Kroesen et al., “Bispecific Antibody-mediated Target Cell-specific Costimulation of Resting T Cells via CD5 and CD28,”Cancer Research55:4409-4415 (Oct. 1, 1995).
P. Kufer et al., “Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer,” Cancer Immunol Immunother (1997) 45: 193-197.
Matthias Mack, et al., “A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity,”Proc. Natl. Acad. Sci. USA, vol. 92, pp. 7021-7025, Jul. 1995.
Matthias Mack et al., “Biologic Properties of a Bispecific Single-Chain Antibody Directed Against 17-1A (EpCAM) and CD3,”The Journal of Immunology, 1997, 158: 3965-3970.
Iain G Martin et al., “Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomas: a potential immunotherapeutic target?”J Clin Pathol1999; 52:701-704.
Susanna A. Möller et al., “Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes,”Cancer Immunol Immunother(1991) 33: 210-216.
J. Packeisen et al., “Detection of Surface Antigen 17-1A in Breast and Colorectal Cancer,”Hybridoma, vol. 18, No. 1,1999.
Bernward Passlick et al., “The 17-1A Antigen Is Expressed on Primary, Metastatic and Disseminated Non-Small Cell Lung Carcinoma Cells,”Int. J. Cancer: 87, 548-552 (2000).
Chandrika J. Piyathilake et al., “The Expression of Ep-CAM (17- 1A) in Squamous Cell Cancers of the Lung,”Human Pathology, vol. 31, No. 4, pp. 482-487, Apr. 2000.
Robert B. Poczatek et al., “Ep-CAM Levels in Prostatic Adenocarcinoma and Prostatic Intraepithelial Neoplasia,”The Journal of Urology, vol. 162, 1462-1466, Oct. 1998.
Tobias Raum et al., “Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens,”Cancer Immunol Immunother(2001) 50: 141-150.
Gerr Riethmüller et al., “Monoclonal Antibody Therapy for Resected Dukes' C Colorectal Cancer: Seven-Year Outcome of a Multicenter Randomized Trial,”Journal of Clinical Oncology, Voi. 16, No. 5, May 1998: pp. 1788-1794.
Gerr Riethmüller et al., “Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma,”The Lancet, vol. 343 No. 8907 pp. 1177-1183, 1994.
Gerr Riethmüller et al., “Monoclonal Antibody (Mab) Adjuvant Therapy of Dukes C Colorectal Carcinoma: 7-Year Update of a Prospective Randomized Trial,”Proceedings of ASCO, vol. 15, Mar. 1996.
Babette Simon et al., “Epithelial glycoprotein is a member of a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein,”Proc. Nati. Acad. Sci. USA, vol. 87, pp. 2755-2759, Apr. 1990.
André Traunecker et al., “Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells,”The EMBO Journal, vol. 10, No. 12, pp. 3655-3659, 1991.
Reinhard Zeidler et al., “Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing,”The Journal of Immunology, 1999, 163: 1246-1252.
Baeuerle Patrick
Berry Meera
Brischwein Klaus
Kohleisen Birgit
Kufer Peter
Foley & Lardner LLP
Micromet AG
Wen Sharon
LandOfFree
Pharmaceutical composition comprising a bispecific antibody... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition comprising a bispecific antibody..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition comprising a bispecific antibody... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2670802